Bisphosphonates do not inhibit periosteal bone formation in estrogen deficient animals and allow enhanced bone modeling in response to mechanical loading
Abstract The suppressive effects of bisphosphonates (BPs) on bone remodeling are clear yet there is conflicting data concerning the effects of BPs on modeling (specifically formation modeling on the periosteal surface). The normal periosteal expansion that occurs during aging has significant benefit...
Gespeichert in:
Veröffentlicht in: | Bone (New York, N.Y.) N.Y.), 2010-01, Vol.46 (1), p.203-207 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 207 |
---|---|
container_issue | 1 |
container_start_page | 203 |
container_title | Bone (New York, N.Y.) |
container_volume | 46 |
creator | Feher, Anthony Koivunemi, Andrew Koivunemi, Mark Fuchs, Robyn K Burr, David B Phipps, Roger J Reinwald, Susan Allen, Matthew R |
description | Abstract The suppressive effects of bisphosphonates (BPs) on bone remodeling are clear yet there is conflicting data concerning the effects of BPs on modeling (specifically formation modeling on the periosteal surface). The normal periosteal expansion that occurs during aging has significant benefits to maintaining/improving the bones' mechanical properties and thus it is important to understand whether BPs affect this bone surface. Therefore, the purpose of this study was to determine the effects of BPs on periosteal bone formation modeling induced by ovariectomy (OVX) and mechanical loading. Six-month-old Sprague–Dawley OVX rats ( n = 60; 12/group) were administered vehicle, risedronate, alendronate, or zoledronate at doses used clinically for treatment of post-menopausal osteoporosis. Three weeks after initiating BP treatment, all animals underwent in vivo ulnar loading of the right limb every other day for 1 week (3 total sessions). Periosteal surface mineral apposition rate, mineralizing surface, and bone formation rate were determined at the mid-diaphysis of both loaded (right) and non-loaded (left) ulnae. There was no significant effect of any of the BPs on periosteal bone formation parameters compared to VEH-treated animals in the non-loaded limb, suggesting that BP treatment does not compromise the normal periosteal expansion associated with estrogen loss. Mechanical loading significantly increased BFR in the loaded limb compared to the non-loaded limb in all BP-treated groups, with no difference in the magnitude of this effect among the various BPs. Collectively, these data show that BP treatment, at doses comparable to those used for treatment of post-menopausal osteoporosis, (1) does not alter the periosteal formation activity that occurs in the absence of estrogen and (2) allows normal stimulation of periosteal bone formation in response to the anabolic stimulation of mechanical loading. |
doi_str_mv | 10.1016/j.bone.2009.10.023 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_733899090</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S8756328209019917</els_id><sourcerecordid>733899090</sourcerecordid><originalsourceid>FETCH-LOGICAL-c440t-ffcaeb507a094d81ef9efab4e40ec331d2aa4d60fec12861120c90d109a582473</originalsourceid><addsrcrecordid>eNp9ks2KFDEUhYMoTjv6Ai4kG3FVbX6qqyogwjj4BwMu1HVIJbem01YlZZJW5lF8W2_oRsGFixAI37nJOSeEPOVsyxnvXh62YwywFYwpPNgyIe-RDR962Yi-k_fJZuh3XSPFIC7Io5wPjDGpev6QXHA17PqOqw359cbndR_rCqZApi7SEAv1Ye9HX-gKycdcwMy0XkanmBZTfAxIUMglxVsI1MHkrYdQqAl-MXPG3VEzz_EnhbA3wYI76ZfoYPbhtsoT5DWGDLREuoBFzFu8Z47GIfGYPJhwEjw575fk67u3X64_NDef3n-8vrppbNuy0kyTNTDuWG-Yat3AYVIwmbGFloGVkjthTOs6NoHlYug4F8wq5jhTZjeItpeX5MVp7pri9yNa0ovPFubZBIjHrHspB6WYYkiKE2lTzDnBpNeEbtOd5kzXRvRBV5O6NlLPsBEUPTuPP44LuL-ScwUIPD8DJqP9KWFaPv_hhJCDEKpD7tWJAwzjh4ekc40ck_UJbNEu-v-_4_U_cos91MC_wR3kQzymgDFrrrPQTH-uf6d-HTTOleK9_A1YqMKP</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733899090</pqid></control><display><type>article</type><title>Bisphosphonates do not inhibit periosteal bone formation in estrogen deficient animals and allow enhanced bone modeling in response to mechanical loading</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Feher, Anthony ; Koivunemi, Andrew ; Koivunemi, Mark ; Fuchs, Robyn K ; Burr, David B ; Phipps, Roger J ; Reinwald, Susan ; Allen, Matthew R</creator><creatorcontrib>Feher, Anthony ; Koivunemi, Andrew ; Koivunemi, Mark ; Fuchs, Robyn K ; Burr, David B ; Phipps, Roger J ; Reinwald, Susan ; Allen, Matthew R</creatorcontrib><description>Abstract The suppressive effects of bisphosphonates (BPs) on bone remodeling are clear yet there is conflicting data concerning the effects of BPs on modeling (specifically formation modeling on the periosteal surface). The normal periosteal expansion that occurs during aging has significant benefits to maintaining/improving the bones' mechanical properties and thus it is important to understand whether BPs affect this bone surface. Therefore, the purpose of this study was to determine the effects of BPs on periosteal bone formation modeling induced by ovariectomy (OVX) and mechanical loading. Six-month-old Sprague–Dawley OVX rats ( n = 60; 12/group) were administered vehicle, risedronate, alendronate, or zoledronate at doses used clinically for treatment of post-menopausal osteoporosis. Three weeks after initiating BP treatment, all animals underwent in vivo ulnar loading of the right limb every other day for 1 week (3 total sessions). Periosteal surface mineral apposition rate, mineralizing surface, and bone formation rate were determined at the mid-diaphysis of both loaded (right) and non-loaded (left) ulnae. There was no significant effect of any of the BPs on periosteal bone formation parameters compared to VEH-treated animals in the non-loaded limb, suggesting that BP treatment does not compromise the normal periosteal expansion associated with estrogen loss. Mechanical loading significantly increased BFR in the loaded limb compared to the non-loaded limb in all BP-treated groups, with no difference in the magnitude of this effect among the various BPs. Collectively, these data show that BP treatment, at doses comparable to those used for treatment of post-menopausal osteoporosis, (1) does not alter the periosteal formation activity that occurs in the absence of estrogen and (2) allows normal stimulation of periosteal bone formation in response to the anabolic stimulation of mechanical loading.</description><identifier>ISSN: 8756-3282</identifier><identifier>EISSN: 1873-2763</identifier><identifier>DOI: 10.1016/j.bone.2009.10.023</identifier><identifier>PMID: 19857619</identifier><language>eng</language><publisher>Amsterdam: Elsevier Inc</publisher><subject>Alendronate ; Alendronate - pharmacology ; Animals ; Biological and medical sciences ; Bone and Bones - drug effects ; Bone Density Conservation Agents - pharmacology ; Bones, joints and connective tissue. Antiinflammatory agents ; Diphosphonates - pharmacology ; Etidronic Acid - analogs & derivatives ; Etidronic Acid - pharmacology ; Female ; Fundamental and applied biological sciences. Psychology ; Imidazoles - pharmacology ; Medical sciences ; Orthopedics ; Osteogenesis - drug effects ; Osteoporosis - drug therapy ; Ovariectomy ; Pharmacology. Drug treatments ; Rats ; Risedronate ; Risedronate Sodium ; Skeleton and joints ; Ulna loading ; Vertebrates: anatomy and physiology, studies on body, several organs or systems ; Vertebrates: osteoarticular system, musculoskeletal system ; Zoledronate</subject><ispartof>Bone (New York, N.Y.), 2010-01, Vol.46 (1), p.203-207</ispartof><rights>Elsevier Inc.</rights><rights>2009 Elsevier Inc.</rights><rights>2015 INIST-CNRS</rights><rights>Copyright (c) 2009 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c440t-ffcaeb507a094d81ef9efab4e40ec331d2aa4d60fec12861120c90d109a582473</citedby><cites>FETCH-LOGICAL-c440t-ffcaeb507a094d81ef9efab4e40ec331d2aa4d60fec12861120c90d109a582473</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.bone.2009.10.023$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22382296$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19857619$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Feher, Anthony</creatorcontrib><creatorcontrib>Koivunemi, Andrew</creatorcontrib><creatorcontrib>Koivunemi, Mark</creatorcontrib><creatorcontrib>Fuchs, Robyn K</creatorcontrib><creatorcontrib>Burr, David B</creatorcontrib><creatorcontrib>Phipps, Roger J</creatorcontrib><creatorcontrib>Reinwald, Susan</creatorcontrib><creatorcontrib>Allen, Matthew R</creatorcontrib><title>Bisphosphonates do not inhibit periosteal bone formation in estrogen deficient animals and allow enhanced bone modeling in response to mechanical loading</title><title>Bone (New York, N.Y.)</title><addtitle>Bone</addtitle><description>Abstract The suppressive effects of bisphosphonates (BPs) on bone remodeling are clear yet there is conflicting data concerning the effects of BPs on modeling (specifically formation modeling on the periosteal surface). The normal periosteal expansion that occurs during aging has significant benefits to maintaining/improving the bones' mechanical properties and thus it is important to understand whether BPs affect this bone surface. Therefore, the purpose of this study was to determine the effects of BPs on periosteal bone formation modeling induced by ovariectomy (OVX) and mechanical loading. Six-month-old Sprague–Dawley OVX rats ( n = 60; 12/group) were administered vehicle, risedronate, alendronate, or zoledronate at doses used clinically for treatment of post-menopausal osteoporosis. Three weeks after initiating BP treatment, all animals underwent in vivo ulnar loading of the right limb every other day for 1 week (3 total sessions). Periosteal surface mineral apposition rate, mineralizing surface, and bone formation rate were determined at the mid-diaphysis of both loaded (right) and non-loaded (left) ulnae. There was no significant effect of any of the BPs on periosteal bone formation parameters compared to VEH-treated animals in the non-loaded limb, suggesting that BP treatment does not compromise the normal periosteal expansion associated with estrogen loss. Mechanical loading significantly increased BFR in the loaded limb compared to the non-loaded limb in all BP-treated groups, with no difference in the magnitude of this effect among the various BPs. Collectively, these data show that BP treatment, at doses comparable to those used for treatment of post-menopausal osteoporosis, (1) does not alter the periosteal formation activity that occurs in the absence of estrogen and (2) allows normal stimulation of periosteal bone formation in response to the anabolic stimulation of mechanical loading.</description><subject>Alendronate</subject><subject>Alendronate - pharmacology</subject><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Bone and Bones - drug effects</subject><subject>Bone Density Conservation Agents - pharmacology</subject><subject>Bones, joints and connective tissue. Antiinflammatory agents</subject><subject>Diphosphonates - pharmacology</subject><subject>Etidronic Acid - analogs & derivatives</subject><subject>Etidronic Acid - pharmacology</subject><subject>Female</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Imidazoles - pharmacology</subject><subject>Medical sciences</subject><subject>Orthopedics</subject><subject>Osteogenesis - drug effects</subject><subject>Osteoporosis - drug therapy</subject><subject>Ovariectomy</subject><subject>Pharmacology. Drug treatments</subject><subject>Rats</subject><subject>Risedronate</subject><subject>Risedronate Sodium</subject><subject>Skeleton and joints</subject><subject>Ulna loading</subject><subject>Vertebrates: anatomy and physiology, studies on body, several organs or systems</subject><subject>Vertebrates: osteoarticular system, musculoskeletal system</subject><subject>Zoledronate</subject><issn>8756-3282</issn><issn>1873-2763</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9ks2KFDEUhYMoTjv6Ai4kG3FVbX6qqyogwjj4BwMu1HVIJbem01YlZZJW5lF8W2_oRsGFixAI37nJOSeEPOVsyxnvXh62YwywFYwpPNgyIe-RDR962Yi-k_fJZuh3XSPFIC7Io5wPjDGpev6QXHA17PqOqw359cbndR_rCqZApi7SEAv1Ye9HX-gKycdcwMy0XkanmBZTfAxIUMglxVsI1MHkrYdQqAl-MXPG3VEzz_EnhbA3wYI76ZfoYPbhtsoT5DWGDLREuoBFzFu8Z47GIfGYPJhwEjw575fk67u3X64_NDef3n-8vrppbNuy0kyTNTDuWG-Yat3AYVIwmbGFloGVkjthTOs6NoHlYug4F8wq5jhTZjeItpeX5MVp7pri9yNa0ovPFubZBIjHrHspB6WYYkiKE2lTzDnBpNeEbtOd5kzXRvRBV5O6NlLPsBEUPTuPP44LuL-ScwUIPD8DJqP9KWFaPv_hhJCDEKpD7tWJAwzjh4ekc40ck_UJbNEu-v-_4_U_cos91MC_wR3kQzymgDFrrrPQTH-uf6d-HTTOleK9_A1YqMKP</recordid><startdate>20100101</startdate><enddate>20100101</enddate><creator>Feher, Anthony</creator><creator>Koivunemi, Andrew</creator><creator>Koivunemi, Mark</creator><creator>Fuchs, Robyn K</creator><creator>Burr, David B</creator><creator>Phipps, Roger J</creator><creator>Reinwald, Susan</creator><creator>Allen, Matthew R</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20100101</creationdate><title>Bisphosphonates do not inhibit periosteal bone formation in estrogen deficient animals and allow enhanced bone modeling in response to mechanical loading</title><author>Feher, Anthony ; Koivunemi, Andrew ; Koivunemi, Mark ; Fuchs, Robyn K ; Burr, David B ; Phipps, Roger J ; Reinwald, Susan ; Allen, Matthew R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c440t-ffcaeb507a094d81ef9efab4e40ec331d2aa4d60fec12861120c90d109a582473</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Alendronate</topic><topic>Alendronate - pharmacology</topic><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Bone and Bones - drug effects</topic><topic>Bone Density Conservation Agents - pharmacology</topic><topic>Bones, joints and connective tissue. Antiinflammatory agents</topic><topic>Diphosphonates - pharmacology</topic><topic>Etidronic Acid - analogs & derivatives</topic><topic>Etidronic Acid - pharmacology</topic><topic>Female</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Imidazoles - pharmacology</topic><topic>Medical sciences</topic><topic>Orthopedics</topic><topic>Osteogenesis - drug effects</topic><topic>Osteoporosis - drug therapy</topic><topic>Ovariectomy</topic><topic>Pharmacology. Drug treatments</topic><topic>Rats</topic><topic>Risedronate</topic><topic>Risedronate Sodium</topic><topic>Skeleton and joints</topic><topic>Ulna loading</topic><topic>Vertebrates: anatomy and physiology, studies on body, several organs or systems</topic><topic>Vertebrates: osteoarticular system, musculoskeletal system</topic><topic>Zoledronate</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Feher, Anthony</creatorcontrib><creatorcontrib>Koivunemi, Andrew</creatorcontrib><creatorcontrib>Koivunemi, Mark</creatorcontrib><creatorcontrib>Fuchs, Robyn K</creatorcontrib><creatorcontrib>Burr, David B</creatorcontrib><creatorcontrib>Phipps, Roger J</creatorcontrib><creatorcontrib>Reinwald, Susan</creatorcontrib><creatorcontrib>Allen, Matthew R</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Bone (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Feher, Anthony</au><au>Koivunemi, Andrew</au><au>Koivunemi, Mark</au><au>Fuchs, Robyn K</au><au>Burr, David B</au><au>Phipps, Roger J</au><au>Reinwald, Susan</au><au>Allen, Matthew R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Bisphosphonates do not inhibit periosteal bone formation in estrogen deficient animals and allow enhanced bone modeling in response to mechanical loading</atitle><jtitle>Bone (New York, N.Y.)</jtitle><addtitle>Bone</addtitle><date>2010-01-01</date><risdate>2010</risdate><volume>46</volume><issue>1</issue><spage>203</spage><epage>207</epage><pages>203-207</pages><issn>8756-3282</issn><eissn>1873-2763</eissn><abstract>Abstract The suppressive effects of bisphosphonates (BPs) on bone remodeling are clear yet there is conflicting data concerning the effects of BPs on modeling (specifically formation modeling on the periosteal surface). The normal periosteal expansion that occurs during aging has significant benefits to maintaining/improving the bones' mechanical properties and thus it is important to understand whether BPs affect this bone surface. Therefore, the purpose of this study was to determine the effects of BPs on periosteal bone formation modeling induced by ovariectomy (OVX) and mechanical loading. Six-month-old Sprague–Dawley OVX rats ( n = 60; 12/group) were administered vehicle, risedronate, alendronate, or zoledronate at doses used clinically for treatment of post-menopausal osteoporosis. Three weeks after initiating BP treatment, all animals underwent in vivo ulnar loading of the right limb every other day for 1 week (3 total sessions). Periosteal surface mineral apposition rate, mineralizing surface, and bone formation rate were determined at the mid-diaphysis of both loaded (right) and non-loaded (left) ulnae. There was no significant effect of any of the BPs on periosteal bone formation parameters compared to VEH-treated animals in the non-loaded limb, suggesting that BP treatment does not compromise the normal periosteal expansion associated with estrogen loss. Mechanical loading significantly increased BFR in the loaded limb compared to the non-loaded limb in all BP-treated groups, with no difference in the magnitude of this effect among the various BPs. Collectively, these data show that BP treatment, at doses comparable to those used for treatment of post-menopausal osteoporosis, (1) does not alter the periosteal formation activity that occurs in the absence of estrogen and (2) allows normal stimulation of periosteal bone formation in response to the anabolic stimulation of mechanical loading.</abstract><cop>Amsterdam</cop><pub>Elsevier Inc</pub><pmid>19857619</pmid><doi>10.1016/j.bone.2009.10.023</doi><tpages>5</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 8756-3282 |
ispartof | Bone (New York, N.Y.), 2010-01, Vol.46 (1), p.203-207 |
issn | 8756-3282 1873-2763 |
language | eng |
recordid | cdi_proquest_miscellaneous_733899090 |
source | MEDLINE; Access via ScienceDirect (Elsevier) |
subjects | Alendronate Alendronate - pharmacology Animals Biological and medical sciences Bone and Bones - drug effects Bone Density Conservation Agents - pharmacology Bones, joints and connective tissue. Antiinflammatory agents Diphosphonates - pharmacology Etidronic Acid - analogs & derivatives Etidronic Acid - pharmacology Female Fundamental and applied biological sciences. Psychology Imidazoles - pharmacology Medical sciences Orthopedics Osteogenesis - drug effects Osteoporosis - drug therapy Ovariectomy Pharmacology. Drug treatments Rats Risedronate Risedronate Sodium Skeleton and joints Ulna loading Vertebrates: anatomy and physiology, studies on body, several organs or systems Vertebrates: osteoarticular system, musculoskeletal system Zoledronate |
title | Bisphosphonates do not inhibit periosteal bone formation in estrogen deficient animals and allow enhanced bone modeling in response to mechanical loading |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T10%3A18%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Bisphosphonates%20do%20not%20inhibit%20periosteal%20bone%20formation%20in%20estrogen%20deficient%20animals%20and%20allow%20enhanced%20bone%20modeling%20in%20response%20to%20mechanical%20loading&rft.jtitle=Bone%20(New%20York,%20N.Y.)&rft.au=Feher,%20Anthony&rft.date=2010-01-01&rft.volume=46&rft.issue=1&rft.spage=203&rft.epage=207&rft.pages=203-207&rft.issn=8756-3282&rft.eissn=1873-2763&rft_id=info:doi/10.1016/j.bone.2009.10.023&rft_dat=%3Cproquest_cross%3E733899090%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=733899090&rft_id=info:pmid/19857619&rft_els_id=1_s2_0_S8756328209019917&rfr_iscdi=true |